Search Press releases Keywords From To 13 Mar 2026 Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees Read More 11 Mar 2026 BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50 Read More 3 Mar 2026 UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody Read More 26 Feb 2026 Strong Execution Fueling Sustained Company Growth Read More 4 Feb 2026 UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements Read More 30 Jan 2026 KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d) Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 60 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
